Simple Summary This is the first known study to compare three FDG-PET/CT criteria
(EORTC, PERCIST, imPERCIST) with CT criteria (combined modified RECIST and RECIST …

For many years, the standard treatment for malignant pleural mesothelioma (MPM) has been
based on chemotherapy agents. In the late twentieth century, cytotoxic drugs were tested …

The treatment paradigm for malignant pleural mesothelioma (MPM) has changed little in the
last 18 years. Radical intent treatment, consisting of surgical resection, radiotherapy and …

Methods Eligibility included: epithelioid or biphasic histology, resectable by pleurectomy/
decortication (P/D) or extrapleural pneumonectomy (EPP), extended surgical staging with …

Background Randomized phase III trials are ongoing to investigate the efficacy of nivolumab
in malignant pleural mesothelioma (MPM), but real-world data are still scarce. In this real …

Malignant pleural mesothelioma (MPM) is the most common form of mesothelioma and the
type most often studied in prospective clinical trials. This review reports the trials that have …

Background Nivolumab is used for the treatment of malignant pleural mesothelioma (MPM).
However, immune-related adverse events (irAEs) occur in patients treated with nivolumab …

Malignant pleural mesothelioma (MPM) is a highly aggressive tumor with a poor prognosis
and an increasing incidence worldwide. The only standard first-line chemotherapy for …

Over the course of the last decade, immunotherapy has revolutionised the management of a
great number of cancer types. The treatment of pleural mesothelioma, a rare and highly …

Malignant pleural mesothelioma (MPM) remains a rare thoracic malignancy with an
incidence in Europe of 1.83 cases per 100 000 individuals annually. 1 Asbestos exposure is …